The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.
JITC's editorial board is led by Editor-in-Chief Dr. Michael Lotze of the University of Pittsburgh. From there, the journal is published with support from a throng of section and associate editors, who review their specific section areas. Click on a section name below to access the full editor list:
Editor-in-Chief
Michael T. Lotze, MD
University of Pittsburgh – United States
Deputy Editor-in-Chief
Sjoerd H. van der Burg, PhD
Oncode Institute & Leiden University Medical Center – Netherlands
Basic and Translational Cancer Immunology Section
Section Editors
Claudia Palena, PhD
National Cancer Institute, National Institutes of Health – United States
Walter J. Storkus, PhD
University of Pittsburgh – United States
Eric Tartour, MD, PhD
Hôpital Européen Georges Pompidou – France
Deputy Editor
Hongbo Hu, PhD
West China Hospital, Sichuan University – China
Associate Editors
Scott I. Abrams, PhD
Roswell Park Comprehensive Cancer Center – United States
Timothy NJ Bullock, PhD
University of Virginia – United States
Gennaro Ciliberto, MD
IRCCS Istituto Nazionale Tumori Regina Elena – Italy
Tanja D. de Gruijl, PhD
Amsterdam University Medical Centers – Netherlands
Jennifer L. Guerriero, PhD
Brigham and Women’s Hospital – United States
Pawel Kalinski, MD, PhD
Roswell Park Comprehensive Cancer Center – United States
Khashayarsha Khazaie, PhD, DSc
Mayo Clinic College of Medicine – United States
Sattva S. Neelapu, MD
The University of Texas MD Anderson Cancer Center – United States
Anna Obenauf, PhD
Research Institute of Molecular Pathology – Austria
Michael Platten, MD
Ruprecht-Karls University Heidelberg – Germany
Gabriel Rabinovich, PhD
Instituto de Biologia y Medicina Experimental (IByME) – Argentina
Alessandro Russo, MD, PhD
Università degli Studi di Messina – Italy
Stefani Spranger, PhD
Massachusetts Institute of Technology – United States
Viktor Umansky, MD, PhD
German Cancer Research Center (DKFZ) – Germany
Louis M. Weiner, MD
Georgetown University Lombardi Cancer Center – United States
Case Reports Section
Section Editor
Sebastian Kobold, MD
Klinikum der Universität München – Germany
Associate Editors
Jack D. Bui, MD, PhD
University of California San Diego – United States
Marco Donia, MD, PhD
National Center for Cancer Immune Therapy (CCIT-DK) – Denmark
Heinz Läubli, MD, PhD
University Hospital Basel – Switzerland
Allison Betof Warner, MD, PhD
Stanford Cancer Center – United States
Clinical Cancer Immunotherapy Section
Section Editors
Jason J. Luke, MD, FACP
UPMC Hillman Cancer Center – United States
Douglas G. McNeel, MD, PhD
University of Wisconsin Carbone Cancer Center – United States
Associate Editors
Paulo Antonio Ascierto, MD
Istituto Nazional Tumori-Fondazione 'G.Pascale' – Italy
Tina Cascone, MD, PhD
The University of Texas MD Anderson Cancer Center – United States
Margaret E. Gatti-Mays, MD, MPH
Ohio State University Comprehensive Cancer Center – United States
Francois Ghiringhelli, PhD
Institut National De La Sante Et De Le Recherche Medicale (INSERM) – France
James J. Harding, MD
Memorial Sloan Kettering Cancer Center – United States
Douglas B. Johnson, MD, MSCI
Vanderbilt University Medical Center – United States
Yangqiu Li, MD
Jinan University School of Medicine – China
Ravi A. Madan, MD
National Cancer Institute, National Institutes of Health – United States
Luca Mazzarella, MD, PhD
European Institute of Oncology – Italy
Kunle Odunsi, MD, PhD
University of Chicago Medicine Comprehensive Cancer Center – United States
Ravi Patel, MD, PhD
University of Pittsburgh – United States
Commentary/Editorials Section
Section Editor
Christian Capitini, MD
University of Wisconsin, Madison – United States
Associate Editors
Ana Carrizosa Anderson, MD
Harvard University – United States
Diwakar Davar, MD
UPMC Hillman Cancer Center – United States
Michael Dougan, MD, PhD
Massachusetts General Hospital – United States
William J. Murphy, PhD
University of California, Davis – United States
Guidelines and Consensus Statements Section
Section Editor
Robert L. Ferris, MD, PhD
UNC Lineberger Comprehensive Cancer Center – United States
Immune Cell Therapies and Immune Cell Engineering Section
Section Editor
Aude Chapuis, MD
Fred Hutchinson Cancer Research Center – United States
Marcela V. Maus, MD, PhD
Massachusetts General Hospital – United States
Associate Editors
Marco L. Davila, MD, PhD
Roswell Park Comprehensive Cancer Center – United States
Joseph A. Fraietta, PhD
University of Pennsylvania – United States
Sara Ghorashian, MD, PhD
University College London – United Kingdom
Michael Hudecek, MD
Universitätsklinikum Würzburg – Germany
Michael D. Kalos, PhD
Next Pillar Consulting – United States
Gerald Linette, MD, PhD
University of Pennsylvania – United States
Daniel J. Powell Jr., PhD
University of Pennsylvania – United States
Marco Ruella, MD
University of Pennsylvania – United States
Lillian Seu, PhD
Revolution Medicines – United States
Nirali N. Shah, MD, MHSc
National Cancer Institute, National Institutes of Health – United States
Eric L. Smith, MD, PhD
Dana-Farber Cancer Institute – United States
Maria Themeli, MD, PhD
VUmc Cancer Center Amsterdam – Netherlands
Immunotherapy Biomarkers Section
Section Editors
Ignacio Melero, MD, PhD
Foundation for Applied Medical Research (FIMA) – Spain
Kurt A. Schalper, MD, PhD
Yale School of Medicine – United States
Alexandra Snyder Charen, MD
Generate Biomedicines – United States
Associate Editors
Maria Ascierto, PhD
University of Glasgow – United Kingdom
Carlo B. Bifulco, MD
Providence Portland Medical Center – United States
John C. Castle, PhD
Monte Rosa Therapeutics – Switzerland
Alessandra Cesano, MD, PhD
ESSA Pharma Inc. – United States
Carlos de Andrea, MD, PhD
University of Navarra– Spain
Eric Deutsch, MD, PhD
Gustave Roussy Cancer Campus – France
Elisabeth G.E. de Vries, MD, PhD
University Medical Centre Groningen – Netherlands
Jolanda de Vries, PhD
Radboud University Nijmegen – Netherlands
Rejean Lapointe, PhD
Universite De Montreal, University Hospital (CRCHUM) – Canada
Christian H. Ottensmeier, MD, PhD, FRCP
University of Southampton – United Kingdom
Graham P. Pawelec, PhD
University of Tuebingen – Germany
Licia Rivoltini, MD
Fondazione IRCCS Istituto Nazionale Tumori – Italy
Barbara Seliger, MD, PhD
Martin Luther University Halle-Wittenberg – Germany
Craig L. Slingluff Jr., MD
University of Virginia – United States
Claudio Tripodo, MD
University of Palermo – Italy
Jinada Yuan, MD, PhD
Merck & Co. – United States
Oncolytic and Local Immunotherapy Section
Section Editor
Howard L. Kaufman, MD, FACS
Massachusetts General Hospital – United States
Associate Editors
Darrel J. Irvine, PhD
Massachusetts Institute of Technology – United States
Samuel Rabkin, PhD
Massachusetts General Hospital – United States
K. Dane Wittrup, PhD
Massachusetts Institute of Technology – United States
Dmitriy Zamarin, MD, PhD
Icahn School of Medicine at Mount Sinai – United States
Reviews Section
Section Editors
Sandra Demaria, MD
Weill Cornell Medical College – United States
Lawrence Fong, MD
Fred Hutchinson Cancer Center – United States
Associate Editors
Ira Mellman, PhD, FAACR, FAIO
Parker Institute for Cancer Immunotherapy, Medici Therapeutics – United States
James J. Mule, PhD
H. Lee Moffitt Cancer Center – United States
Specialty Editors
Consulting Editor, Special Series and Reviews
Pedro J. Romero, MD
Novigenix – Switzerland
Consulting Editor
Thomas F. Gajewski, MD, PhD
University of Chicago – United States
Social Media Editors
Kristin G. Anderson, PhD
University of Virginia – United States
Praveen Bommareddy, PhD, MS
Replimune, Inc. – United States
Cheng Sun, MD, PhD
University of Science and Technology of China, Hefei – China